• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

A psycho‐oncological online intervention supporting partners of patients with cancer (PartnerCARE): Results from a randomized controlled feasibility trial

Abstract

Objective

Partners of cancer patients are the primary supporters and burdened at the same time. Support for partners is hitherto scarce and existing offers are rarely used. The PartnerCARE online intervention was specifically developed to address the caregiving partners’ needs. This two-arm parallel randomized controlled trial evaluates the feasibility, acceptability, and potential efficacy of PartnerCARE.

Methods

Sixty German-speaking partners of patients with various cancer entities were randomized into two conditions: intervention group with PartnerCARE (N=30) or waitlist-control group (N=30). Participants completed online questionnaires at baseline (T0), post-treatment (T1) and four-months follow-up (T2). Feasibility and acceptability outcomes included dropout rates, use and acceptance of PartnerCARE, individual user/e-coach feedback as well as negative effects. Relevant efficacy outcomes were assessed to test for potential intervention effects.

Results

Recruitment success illustrates demand for and acceptability of PartnerCARE. Satisfaction with the intervention was high (CSQ-I, T1: M=24.66, SD=6.42) and 73.3 % of participants completed the intervention. Study dropout rate was low (T1: 17%, T2: 29%). More positive than negative side effects of the intervention were identified, and negative ones were mainly related to ‘intrapersonal change’. For efficacy outcomes we found effects over time, with strongest effects within the intervention group from T0 to T1 in psychological distress (d=0.73, 95%-CI: [0.34; 1.12]) and anxiety (0.66, [0.26; 1.04]), but no group effects were significant at T1 and T2.

Conclusions

PartnerCARE is feasible, acceptable and potentially efficacious. Based on received feedback, PartnerCARE is currently undergoing further development and subsequently efficacy will be investigated in a randomized controlled trial.

This article is protected by copyright. All rights reserved.

Read the full article ›

Posted in: Journal Article Abstracts on 04/05/2022 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice